mRNA Patent Settlement Could Reach 3 Trillion Won.. A Bold Move for Rare Disease New Drugs

Roivant Sciences Ltd. (NYSE: ROIV) has struck an agreement with affiliates Genevant and Arbutus to settle a global patent dispute over lipid nanoparticle (LNP) technology used in Moderna’s mRNA vaccines for up to $2.25 billion (approximately 3 trillion KRW). The deal secures a $950 million upfront payment (about 1.2 trillion KRW) by July 2026, with the potential for up to $1.3 billion (around 1.7 trillion KRW) in contingent payments.

On March 17, Eric Banker, CEO of subsidiary Immunovant, exercised stock options and sold all of his common shares, realizing roughly $6 million (around 7 billion KRW) and slightly reducing his direct holdings; however, he retains the right to acquire additional shares through long-dated options.

In an April 2 announcement, subsidiary Priovant said it has initiated potentially registrational Phase 2b/3 trials of brepocitinib for lichen planopilaris (LPP), a rare inflammatory scalp disease. Meanwhile, its Phase 3 trial of batoclimab for thyroid eye disease (TED) failed to meet the primary efficacy endpoint, prompting a strategic review with partner HanAll BioPharma. Priovant also highlighted IMVT-1402 as a core pipeline asset targeting multiple autoimmune diseases, including Graves’ disease, with potential pivotal data expected in 2027. ()

According to recent filings and reports, Roivant has approved a new share repurchase program of up to $1 billion alongside the $2.25 billion settlement announcement involving Genevant, Arbutus, and Moderna. Results from the Phase 3 VALOR trial of brepocitinib in dermatomyositis were published in the New England Journal of Medicine at the end of March and are under priority review by the FDA, targeting a U.S. launch in September 2026. ()

Roivant operates as a platform biotech company, housing assets across multiple “-vant” subsidiaries to pursue growth through its immunology and rare disease–focused pipeline alongside the LNP patent portfolio of affiliate Genevant. Given the high valuation volatility in the U.S. biotech sector—driven by late-stage clinical outcomes, licensing deals, and M&A—upcoming data on key assets such as brepocitinib and IMVT-1402, as well as deal structures with major pharmaceutical partners, will likely determine Roivant’s future performance and share price. ()